Literature DB >> 9779381

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.

D E Low1.   

Abstract

During the last decade there has been an unexpectedly rapid evolution of antimicrobial resistance in the respiratory pathogens for community- and hospital-acquired pneumonia. In order to choose the most optimal therapy for their patients, it is essential that physicians be aware of the prevalence and mechanisms of resistance and their implications on the effectiveness of the various antimicrobials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779381     DOI: 10.1016/s0891-5520(05)70201-4

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  4 in total

1.  Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.

Authors:  Ayman M Noreddin; Danielle Roberts; Kim Nichol; Aleksandra Wierzbowski; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Aerobic Gram-negative Bacillary Pneumonia.

Authors:  Stephen Parodi; Matthew Bidwell Goetz
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

3.  Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Tracy Bellyou; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.